Eledon Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Eledon Pharmaceuticals, Inc. (ELDN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 3.88% for the 12-month period ending 2023-12-31, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2024-11-12
- Eledon Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.20%, a 320.00% increase from fiscal 2021.
- Eledon Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.00%, a 66.67% decline from fiscal 2020.
- Eledon Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2020 was 3.00%, a 0.00% change from fiscal 2019.
- Eledon Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2019 was 3.00%, a 0.00% change from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month as first filed |
|---|---|---|
| 2023-12-31 | 3.88% 10-Q · filed 2024-11-12 | |
| 2022-12-31 | 4.20% 10-K · filed 2023-03-30 | |
| 2021-12-31 | 1.00% 10-K · filed 2022-03-24 | |
| 2020-12-31 | 3.00% 10-K · filed 2022-03-24 | 1.00% 10-K · filed 2021-03-31 |
| 2019-12-31 | 3.00% 10-K · filed 2021-03-31 | |
| 2018-12-31 | 3.00% 10-K · filed 2020-03-17 | |
| 2017-12-31 | 3.00% 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |